Gastric and Esophageal

Colon, Lung, Other Digestive Organ, Pancreas, Phase IPhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Colon, Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Lung, Other Digestive Organ, Pancreas, Phase I, Rectum, Small Intestine, StomachA Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Esophagus, Other Endocrine System, StomachA Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3)
Esophagus, StomachProtocol EA2234: A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis - STOPGAP II
Esophagus, StomachA Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)Principal Investigator: Raghav Sundar